144 related articles for article (PubMed ID: 37341998)
1. Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.
Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
[TBL] [Abstract][Full Text] [Related]
3. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
4. A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.
Zhang X; Min S; Yang Y; Ding D; Li Q; Liu S; Tao T; Zhang M; Li B; Zhao S; Ge R; Yang F; Li Y; He X; Ma X; Wang L; Wu T; Wang T; Wang G
Front Immunol; 2022; 13():876355. PubMed ID: 35837383
[TBL] [Abstract][Full Text] [Related]
5. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
6. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
10. Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.
Zhou B; Gao S
Cancer Immunol Immunother; 2022 May; 71(5):1183-1197. PubMed ID: 34635925
[TBL] [Abstract][Full Text] [Related]
11. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
[TBL] [Abstract][Full Text] [Related]
13. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
14. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
Wang Y; Zhang G; Wang R
Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
[TBL] [Abstract][Full Text] [Related]
15. Matrix-Metalloprotease Resistant Mucin-16 (MUC16) Peptide Mutants Represent a Worse Lung Adenocarcinoma Outcome.
Patel JS; Callahan BM; Chobrutskiy BI; Blanck G
Proteomics Clin Appl; 2019 Jul; 13(4):e1800155. PubMed ID: 30790454
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
17. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
Front Immunol; 2022; 13():992626. PubMed ID: 36311724
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
19. A New Prognostic Indicator of Immune Microenvironment and Therapeutic Response in Lung Adenocarcinoma Based on Peroxisome-Related Genes.
Xiong Z; Zhang L; Fan W
J Immunol Res; 2022; 2022():6084589. PubMed ID: 35935579
[TBL] [Abstract][Full Text] [Related]
20. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]